{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03947385",
            "orgStudyIdInfo": {
                "id": "IDE196-001"
            },
            "organization": {
                "fullName": "IDEAYA Biosciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
            "officialTitle": "A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-in-patients-with-solid-tumors-harboring-gnaq-mutations-or-prkc-fusions"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-06-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-05-09",
            "studyFirstSubmitQcDate": "2019-05-09",
            "studyFirstPostDateStruct": {
                "date": "2019-05-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-17",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "IDEAYA Biosciences",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.\n\nPhase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.\n\nPhase 1 Tablet and Food Effect Pharmacokinetic (PK) Substudy will assess the PK profile of IDE196 tablet and evaluate the effects of food on the PK profile of IDE196 tablet\n\nPhase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.\n\nPhase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study.\n\nCrizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Uveal Melanoma",
                "Cutaneous Melanoma",
                "Colorectal Cancer",
                "Other Solid Tumors"
            ],
            "keywords": [
                "Metastatic Uveal Melanoma",
                "Uveal Melanoma",
                "Protein Kinase C",
                "Ophthalmology",
                "Ocular Oncology",
                "Darovasertib",
                "IDE196",
                "Ocular Melanoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 278,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "IDE196 dosed orally, twice daily (BID) for each 28-day cycle",
                    "interventionNames": [
                        "Drug: IDE196"
                    ]
                },
                {
                    "label": "Dose Expansion Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations or PRKC fusions (cutaneous melanoma, CRC, other solid tumors)",
                    "interventionNames": [
                        "Drug: IDE196"
                    ]
                },
                {
                    "label": "Dose Escalation Binimetinib Combination",
                    "type": "EXPERIMENTAL",
                    "description": "IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Binimetinib dosed orally, twice daily (BID) for each 28-day cycle",
                    "interventionNames": [
                        "Drug: IDE196",
                        "Drug: Binimetinib"
                    ]
                },
                {
                    "label": "Dose Expansion Binimetinib Combination",
                    "type": "EXPERIMENTAL",
                    "description": "RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)",
                    "interventionNames": [
                        "Drug: IDE196",
                        "Drug: Binimetinib"
                    ]
                },
                {
                    "label": "Dose Escalation Crizotinib Combination",
                    "type": "EXPERIMENTAL",
                    "description": "IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle",
                    "interventionNames": [
                        "Drug: IDE196",
                        "Drug: Crizotinib"
                    ]
                },
                {
                    "label": "Dose Expansion Crizotinib Combination",
                    "type": "EXPERIMENTAL",
                    "description": "RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)",
                    "interventionNames": [
                        "Drug: IDE196",
                        "Drug: Crizotinib"
                    ]
                },
                {
                    "label": "Dose Optimization Crizotinib Combination",
                    "type": "EXPERIMENTAL",
                    "description": "IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle",
                    "interventionNames": [
                        "Drug: IDE196",
                        "Drug: Crizotinib"
                    ]
                },
                {
                    "label": "Crizotinib Monotherapy with Crossover to Combination",
                    "type": "EXPERIMENTAL",
                    "description": "Crizotinib dosed orally, twice daily (BID) for each 28-day cycle until disease progression then IDE196 added and dosed orally, twice daily (BID) for each 28-day cycle",
                    "interventionNames": [
                        "Drug: IDE196",
                        "Drug: Crizotinib"
                    ]
                },
                {
                    "label": "Tablet PK Substudy",
                    "type": "EXPERIMENTAL",
                    "description": "IDE196 dosed orally, once on Cycle 1 Day 1; thereafter, twice daily (BID) for each 28-day cycle",
                    "interventionNames": [
                        "Drug: IDE196"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "IDE196",
                    "description": "IDE196 dosed orally, twice daily for each 28-day cycle",
                    "armGroupLabels": [
                        "Crizotinib Monotherapy with Crossover to Combination",
                        "Dose Escalation Binimetinib Combination",
                        "Dose Escalation Crizotinib Combination",
                        "Dose Escalation Monotherapy",
                        "Dose Expansion Binimetinib Combination",
                        "Dose Expansion Crizotinib Combination",
                        "Dose Expansion Monotherapy",
                        "Dose Optimization Crizotinib Combination",
                        "Tablet PK Substudy"
                    ],
                    "otherNames": [
                        "Protein Kinase C (PKC) Inhibitor"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Binimetinib",
                    "description": "Binimetinib dosed orally, twice daily for each 28-day cycle",
                    "armGroupLabels": [
                        "Dose Escalation Binimetinib Combination",
                        "Dose Expansion Binimetinib Combination"
                    ],
                    "otherNames": [
                        "MEKTOVI"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Crizotinib",
                    "description": "Crizotinib dosed orally, twice daily for each 28-day cycle",
                    "armGroupLabels": [
                        "Crizotinib Monotherapy with Crossover to Combination",
                        "Dose Escalation Crizotinib Combination",
                        "Dose Expansion Crizotinib Combination",
                        "Dose Optimization Crizotinib Combination"
                    ],
                    "otherNames": [
                        "XALKORI"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose-limiting Toxicity (DLT)",
                    "description": "Determine DLT of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib",
                    "timeFrame": "28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib"
                },
                {
                    "measure": "Maximum Tolerated Dose (MTD)",
                    "description": "Determine MTD of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib",
                    "timeFrame": "28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib"
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with Crizotinib",
                    "description": "Determine RP2D of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib",
                    "timeFrame": "Approx. 6 months"
                },
                {
                    "measure": "Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib",
                    "description": "Pharmacokinetics of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib",
                    "timeFrame": "Approx. 6 months"
                },
                {
                    "measure": "Plasma Concentrations of Crizotinib administered in combination with IDE196",
                    "description": "Pharmacokinetics of Crizotinib in combination with IDE196",
                    "timeFrame": "Approx. 6 months"
                },
                {
                    "measure": "Plasma Concentrations of Binimetinib administered in combination with IDE196",
                    "description": "Pharmacokinetics of Binimetinib in combination with IDE196",
                    "timeFrame": "Approx. 6 months"
                },
                {
                    "measure": "Overall Response Rate (ORR) for combination with Binimetinib or in combination with Crizotinib Dose Expansion by Blinded Independent Review Committee",
                    "description": "Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) criteria",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Duration of Response for combination with Binimetinib or in combination with Crizotinib Dose Expansion by Blinded Independent Review Committee",
                    "description": "RECIST v1.1",
                    "timeFrame": "Approx. 48 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Response Rate (ORR) for combination with Binimetinib or in combination with Crizotinib in Dose Escalation and all combination cohorts by Blinded Independent Review Committee",
                    "description": "Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) criteria",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Duration of Response for combination with Binimetinib or in combination with Crizotinib in Dose Escalation and in all combination cohorts by Blinded Independent Review Committee",
                    "description": "RECIST v1.1",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "ORR by Investigator",
                    "description": "RECIST v1.1",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Duration of Response by Investigator",
                    "description": "RECIST v1.1",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Disease Control by Investigator",
                    "description": "RECIST v1.1",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Numbers of Participants with Adverse Events",
                    "description": "Safety and tolerability of IDE196 either as monotherapy, in combination with Binimetinib, or in combination with Crizotinib",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Treatment-related pharmacodynamic effect in all patients",
                    "description": "Modulation of signaling proteins in PKC, MAPK, and MET pathways",
                    "timeFrame": "Approx. 48 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Progression-Free Survival",
                    "description": "RECIST v1.1",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Overall Survival",
                    "description": "From date of First Dose to End of Follow-up",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Reduction in tumor burden by total volumetric measurement",
                    "description": "Maximum reduction in tumor burden relative to response",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Treatment-related gene signatures and/or molecular profiling",
                    "description": "Modulation of gene signatures and/or molecular profiles",
                    "timeFrame": "Approx. 48 months"
                },
                {
                    "measure": "Treatment-related changes in tumor tissue or cell-free DNA from blood",
                    "description": "Modulation of tissue or cell-free DNA expression",
                    "timeFrame": "Approx. 48 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must be \u226518 years of age\n* Diagnosis of one of the following:\n\n  * MUM: Uveal melanoma with histological or cytological confirmed metastatic disease. Or\n  * Non-MUM: Advanced cutaneous melanoma, colorectal cancer, or other solid tumor that has progressed following prior standard therapies or that has no satisfactory alternative therapies and has evidence of GNAQ/11 hotspot mutation\n* Measurable disease\n* Eastern Cooperative Oncology Group \u22641 and expected life expectancy of \\> 3 months\n* Adequate organ function at screening\n* Adequate contraceptive measures for non-sterilized male and female patients of childbearing potential\n\nBinimetinib Combination Additional Inclusion Criteria:\n\n\u2022 Adequate cardiac function represented by left ventricular ejection fraction (LVEF) \u2265 50%\n\nCrizotinib Combination Additional Inclusion Criteria:\n\n* Prior chemotherapy other therapies as applicable or major surgeries must have been completed at least 4 weeks prior to initiation of crizotinib\n* Patients with preexisting peripheral neuropathy can be included if it is Grade 1 or lower, prior to initiation of crizotinib\n\nExclusion Criteria:\n\n* Known symptomatic brain metastases\n* Previous treatment with a PKC inhibitor\n* Known MSI-H/dMMR tumors who have not previously received immune checkpoint inhibitors\n* Adverse events from prior anti-cancer therapy that have not resolved\n* Known acquired immunodeficiency syndrome (AIDS)-related illness, hepatitis B virus, or hepatitis C virus\n* Active infection requiring ongoing therapy\n* Recent surgery or radiotherapy\n* Prior gastrectomy or upper bowel removal or any other gastrointestinal disorder or defect\n* Females who are pregnant or breastfeeding\n* Impaired cardiac function\n* Treatment with prohibited medications that cannot be discontinued prior to study entry\n* For patients receiving IDE196 powder-in-capsule (PIC) formulation or crizotinib, allergy to mammalian meat products and gelatin\n\nBinimetinib Combination Additional Exclusion Criteria\n\n* Prior treatment with a MEK inhibitor\n* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO\n* History of interstitial lung disease\n* History of thromboembolic or cerebrovascular events \u2264 12 weeks prior to first dose\n* Concurrent neuromuscular disorders that are associated with elevated creatine phosphokinase (CPK)\n* Uncontrolled arterial hypertension despite medical treatment\n* Allergy to binimetinib or its components\n* History of syncope\n\nCrizotinib Combination Additional Exclusion Criteria:\n\n* Prior therapy directly targeting ALK, MET, or ROS1\n* Spinal cord compression\n* History of pneumonitis or interstitial lung disease\n* History of syncope",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "IDEAYA Clinical Trials",
                    "role": "CONTACT",
                    "phone": "+1 650 534 3616",
                    "email": "IDEAYAClinicalTrials@ideayabio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jasgit Sachdev, MD",
                    "affiliation": "jsachdev@ideayabio.com",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "HonorHealth Research Institute",
                    "status": "COMPLETED",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85258",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "UCLA Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bartosz Chmielowski, MD",
                            "role": "CONTACT",
                            "email": "BChmielowski@mednet.ucla.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "San Francisco Oncology Associates",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94115",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "clinicalresearch@sutterhealth.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Florida Cancer Specialist South",
                    "status": "COMPLETED",
                    "city": "Fort Myers",
                    "state": "Florida",
                    "zip": "33901",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.62168,
                        "lon": -81.84059
                    }
                },
                {
                    "facility": "Florida Cancer Specialist North",
                    "status": "COMPLETED",
                    "city": "Saint Petersburg",
                    "state": "Florida",
                    "zip": "33705",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.77086,
                        "lon": -82.67927
                    }
                },
                {
                    "facility": "Mosaic Life Care",
                    "status": "COMPLETED",
                    "city": "Saint Joseph",
                    "state": "Missouri",
                    "zip": "64507",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.76861,
                        "lon": -94.84663
                    }
                },
                {
                    "facility": "Columbia University Medical Center - Herbert Irving Pavilion",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shaheer Khan, MD",
                            "role": "CONTACT",
                            "email": "sk4488@cumc.columbia.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Duke University Medical Center",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Carol A Wiggs",
                            "role": "CONTACT",
                            "email": "cao13@duke.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "University of Cincinnati Cancer Center",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45267",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "513-584-7698"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Sidney Kimmel Cancer Center at Thomas Jefferson University",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19107",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Marlana Orloff, MD",
                            "role": "CONTACT",
                            "email": "marlana.orloff@jefferson.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "The Sarah Cannon Research Institute/Tennessee Oncology",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "askSARAH",
                            "role": "CONTACT",
                            "phone": "844-482-4812"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jordi Ahnert, MD",
                            "role": "CONTACT",
                            "email": "JRodon@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Westmead Hospital",
                    "status": "RECRUITING",
                    "city": "Sydney",
                    "state": "New South Wales",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Matteo Carlino, MD",
                            "role": "CONTACT",
                            "phone": "+61 288 905 200"
                        },
                        {
                            "role": "CONTACT",
                            "phone": "02 8890 5200"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.86785,
                        "lon": 151.20732
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "OPG 7-815",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Melissa Da Ponte",
                            "role": "CONTACT",
                            "phone": "416-946-4501",
                            "phoneExt": "5485",
                            "email": "Melissa.DaPonte@uhn.ca"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3212",
                    "name": "Melanoma, Cutaneous Malignant",
                    "relevance": "LOW"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3099",
                    "name": "Intraocular Melanoma",
                    "asFound": "Uveal Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4192",
                    "name": "Ocular Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077547",
                    "term": "Crizotinib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000092004",
                    "term": "Tyrosine Kinase Inhibitors"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1825",
                    "name": "Crizotinib",
                    "asFound": "Supplemental",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2889",
                    "name": "Tyrosine Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T114",
                    "name": "Chrysanthemum",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "HB",
                    "name": "Herbal and Botanical"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}